A carregar...
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H(1)-antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes...
Na minha lista:
| Publicado no: | Allergy |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5915348/ https://ncbi.nlm.nih.gov/pubmed/27861988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.13083 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|